| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by (used in) investing activities | 44,576 | 38,665 |
| Proceeds from exercise of stock options | 1 | 1 |
| Payments of tax withholdings related to vesting of restricted stock units | 558 | 441 |
| Net cash (used in) provided by financing activities | -557 | -440 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | -4,409 | 2,080 |
| Cash and cash equivalents at beginning of period | 40,016 | - |
| Cash and cash equivalents at end of period | 35,607 | - |
Acrivon Therapeutics, Inc. (ACRV)
Acrivon Therapeutics, Inc. (ACRV)